A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder, Major

Interventions

DRUG: JNJ-42847922
DRUG: Placebo Matching to JNJ-42847922
DRUG: Quetiapine XR
DRUG: Placebo Matching to Quetiapine XR
DRUG: Selective Serotonin Reuptake Inhibitor (SSRI)
DRUG: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)

Sponsor

Janssen Research & Development, LLC